Lilly recruiting Phase 2 of LY3457263 added to semaglutide or tirzepatide
The double-blind trial enrolls type 2 diabetes patients who missed HbA1c goal on a stable incretin dose, with participation lasting about nine months.
PR
By Priya Raman · Science Reporter
Oct 9 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT06897475 tests once-weekly subcutaneous LY3457263 against placebo on change in HbA1c in type 2 diabetes patients already on stable semaglutide or tirzepatide; it started 28 March 2025 and is recruiting.
- 02The design targets incretin non-responders, a group clinicians increasingly face as GLP-1 and GIP/GLP-1 use matures.
- 03Eli Lilly is the sponsor; no enrollment target, dose levels or readout date are listed in the registry entry.
From the source
Read at clinicaltrials.govA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475 · PHASE2 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Type 2 Diabetes.
Source URL https://clinicaltrials.gov/study/NCT06897475
